Paper Details

  1. Home
  2. Paper Details

Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia.

Author: AwadS A, GajewskiJ B

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Oxybutynin was found to be more effective than propantheline in treating detrusor hyperreflexia in patients with multiple sclerosis. While both drugs had comparable neurological, urological, and urodynamic status before treatment, oxybutynin led to better symptomatic responses in a larger percentage of patients. Side effects were experienced by 21% of patients taking oxybutynin and 27% taking propantheline.
Paper Details　
Original Abstract of the Article :
Hyperreflexia is the most common urological finding in patients with multiple sclerosis. A prospective randomized study was done to compare the effectiveness of 2 commonly used drugs, oxybutynin and propantheline. Of the 34 patients entered into the trial 19 were treated with oxybutynin and 15 with ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0022-5347(17)45940-4

データ提供：米国国立医学図書館（NLM）

Easing the Burden of Detrusor Hyperreflexia in Multiple Sclerosis

Multiple sclerosis (MS), an autoimmune disease affecting the central nervous system, can lead to various complications, including detrusor hyperreflexia, a condition characterized by involuntary bladder contractions. This research compares the effectiveness of two commonly used drugs, oxybutynin and propantheline, in treating detrusor hyperreflexia in patients with MS. The study delves into the complexities of bladder dysfunction in MS, seeking to identify effective and well-tolerated treatment options for this debilitating condition.

A Comparative Study: Oxybutynin vs. Propantheline

The researchers conducted a prospective randomized trial, comparing the efficacy of oxybutynin and propantheline in patients with MS and detrusor hyperreflexia. Their findings suggest that oxybutynin was more effective than propantheline in reducing urinary symptoms and improving bladder function. The study also revealed that both drugs had similar side effect profiles, with a significant portion of patients experiencing adverse effects that led to treatment discontinuation.

Finding Relief: A Path to Improved Bladder Control

This research offers valuable insights for clinicians treating detrusor hyperreflexia in patients with MS. The study suggests that oxybutynin may be a preferred option for managing urinary symptoms, potentially improving bladder control and reducing the need for frequent urination. It's like finding a reliable desert well, providing a source of relief and a path to greater comfort and control.

Dr. Camel's Conclusion

Detrusor hyperreflexia can significantly impact the quality of life for individuals with MS, but this research suggests that oxybutynin may be a more effective treatment option compared to propantheline. While both drugs have similar side effect profiles, oxybutynin appears to offer greater relief from urinary symptoms. It's a reminder that even in the challenging landscape of MS, research and innovation can lead to improvements in treatment strategies, offering hope for a better quality of life for those affected.
Date :
  1. Date Completed 1986-05-20
  2. Date Revised 2019-06-21
Further Info :

Pubmed ID

3959249

DOI: Digital Object Identifier

10.1016/s0022-5347(17)45940-4

Related Literature

Article Analysis
・Side Effects of propantheline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.